FDA Gives Go-ahead to Bayer’s CONTOUR


By: Diabetes Health Staff

The US Food and Drug Administration has okayed US sales of Bayer HealthCare’s CONTOUR® Next EZ blood glucose monitoring system. The new BGM, currently available in other countries as the CONTOUR XT, will be available in the US market this summer.

In a statement introducing the new BGM, Bayer says that it contains proprietary new blood glucose sensor technology whose accuracy “notably exceeds” the requirements of ISO 15197:2003. ISO 15197:2003, issued by the International Organization for Standardization, sets the requirements for accuracy in blood glucose monitoring systems used on a self-test basis to manage diabetes.

Bayer says the system’s proprietary electrochemical mediator and meter algorithm provide “a stable, high signal-to-noise ratio that facilitates accurate determination of blood glucose readings, even at low blood glucose levels.” The technology, according to Bayer, ensures that the system remains accurate under a wide range of storage conditions, corrects for common errors, and is not affected by hematocrit or many common interfering substances in the blood, such as acetaminophen or vitamin C.



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.